E2F1 and cancer: E2F1 is deregulated in the setting of human cancers including breast, colorectal, lung, prostate, ovarian, and bladder cancer (Chun et al., 2020; Logotheti et al., 2020; Jing et al., 2022; Priyanka et al., 2022; Yu et al., 2023).